Abstract
Histone deacetylase (HDAC) inhibitors have been shown to enhance the effects of 5-fluorouracil (5-FU) against various cancer cells; however, no report has shown that an HDAC inhibitor may enhance the effects of 5-FU with radiation. Therefore, we investigated whether the novel HDAC inhibitor OBP-801/YM753 could enhance the effects of 5-FU with radiation on esophageal squamous carcinoma KYSE170 cells. The inhibition of the cell growth was significantly stronger with the combination of OBP-801/YM753 with 5-FU than with the 5-FU treatment only. Furthermore, inhibition of the colony formation was the most effective with the combined treatment of OBP-801/YM753, 5-FU, and radiation. Western blot analysis showed that OBP-801/YM753 suppressed the expression of thymidylate synthase induced by 5-FU. Therefore, this three-combined therapy is promising for patients with esophageal squamous carcinoma.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / radiotherapy*
-
Cell Growth Processes / drug effects
-
Cell Growth Processes / radiation effects
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Cell Survival / radiation effects
-
Chemoradiotherapy
-
Depsipeptides
-
Drug Synergism
-
Enzyme Induction / drug effects
-
Esophageal Neoplasms / drug therapy*
-
Esophageal Neoplasms / radiotherapy*
-
Esophageal Squamous Cell Carcinoma
-
Fluorouracil / administration & dosage
-
Fluorouracil / pharmacology*
-
Histone Deacetylase Inhibitors / administration & dosage
-
Histone Deacetylase Inhibitors / pharmacology*
-
Humans
-
Peptides, Cyclic / administration & dosage
-
Peptides, Cyclic / pharmacology*
-
Thymidylate Synthase / biosynthesis
Substances
-
Fluorouracil
-
Histone Deacetylase Inhibitors
-
Peptides, Cyclic
-
Thymidylate Synthase
-
YM753 compound
-
Depsipeptides